Skip to main content
Premium Trial:

Request an Annual Quote

Exact Sciences Nets $64.7M from Stock Offering

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Exact Sciences has completed its public offering of common stock, raising net proceeds of roughly $64.7 million.

The Madison, Wis.-based molecular diagnostics firm sold 11.5 million shares, which included an over-allotment option of 1.5 million shares, at $6 per share. The firm launched the offering last week.

Exact Sciences said that it will use the proceeds from the offering to support clinical trials of its stool-based DNA colorectal cancer screening test. In addition, the funds may be used "strategic initiatives," it said.

Two weeks ago, the firm presented results from a validation study for the test.

In early Wednesday trade on the Nasdaq, shares of Exact Sciences were down 2 percent at $6.13.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.